1. Boster A, et al. Annual relapse rates in multiple sclerosis patients treated with different disease-modify therapies – findings from a real world setting. ECTRIMS 2016; Abstract EP1481.
2. Fachinformation Tecfidera®, Stand: November 2016.
3. Fox RJ, et al. Absolute lymphocyte count and lymphocyte subset profiles during long-term treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis. ECTRIMS 2016; Abstract P716.
4. Gold R, et al. Seven-year follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: integrated analysis of DEFINE, CONFIRM, and ENDORSE. ECTRIMS 2016; Abstract P631.
5. Gold R, et al. Therapieziele und Therapiemanagement bei schubförmig-remittierender multipler Sklerose. Nervenheilkunde 2015;34:915–23.
6. Leray E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010;133:1900–13.
7. Miclea A, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol 2016;263:1626–32.
8. Scalfari A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;33:1914–29.
9. Spelman T, et al. Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide. ECTRIMS 2016; Abstract P1157.
10. Zhu B, et al. Delayed-release dimethyl fumarate does not adversely affect the pharmacokinetics of a commonly used oral contraceptive (norgestimate/ethinyl estradiol) in healthy women: Drug-drug interaction study results. AAN 2016; Abstract P2.097.